Albion News

  London UK, 3 October 2018 Locum’s Nest, the app that connects doctors to locum work in hospitals, has today announced it has raised £3m in further funding from Albion Capital, the leading independent investment manager, and IDO Investments. The new funding takes the total investment in Locum’s Nest to £4.1 million. Locum’s Nest is the mobile-first platform connecting doctors to temporary work in healthcare organisations, while helping hospital staff managers cut out the inefficient and expensive agency middleman. Traditionally, hospitals looking for locum staff to fill empty shifts pay... read more
10 September 2018 – Arecor, the UK-based biopharmaceutical formulation company, has raised £6 million from new and existing investors to develop groundbreaking pharmaceutical drugs to transform the treatment of diabetes. The fundraising was led by Calculus Capital, Albion Capital, and Downing Ventures.  BioScience Managers Limited, the international healthcare investment firm, advised Downing Ventures.Through the application of its technology platform, Arecor is creating faster working, more effective drugs that help progress the creation of the next generation of artificial pancreas systems... read more
Fishmongers' Hall.jpg
Many thanks to all those that joined us at The Fishmongers' Hall for another very successful seminar The slides from the event will be available shortly read more
Funding led by the UCL Technology Fund with participation from: Nationwide Building Society, Pentland, Amadeus Capital Partners and AI Seed Hazy, the London-based AI company enabling ethical, effortless and GDPR-compliant data sharing for responsible businesses, has announced an additional $1.8 million seed funding led by UCL Technology Fund, alongside Nationwide Building Society, Pentland, Amadeus Capital Partners, AI Seed and other investors. This takes Hazy’s total seed funding to $2.8 million following a $1 million investment from M12 and Notion, awarded to the company in May, after Hazy... read more
Big Data and Enterprise Intelligence scale-up Quantexa has secured USD20 million (GBP15.2 million) in Series B funding. Albion Capital participated in the round, led by Dawn Capital, with return backers HSBC also participating. The new funding will be used to further develop Quantexa’s unique technology and support its international expansion. The investment follows continued success this year as the firm announced partnerships with Deloitte and HSBC to help prevent money-laundering activity and improving customer insight with Shell. British Patient Capital, the new wholly-owned commercial... read more
Orchard Therapeutics
UCLTF funded Orchard Therapeutics, a biotechnology company dedicated to transforming the lives of patients with rare disorders through innovative gene therapies, today announced the completion of an oversubscribed $150 million Series C financing.is one of the early Deerfield Management led the financing with significant new investments from RA Capital Management, Venrock, Foresite Capital, Perceptive Advisors, Cormorant Asset Management LP, ArrowMark Partners, Sphera Global Healthcare, Medison Ventures, Driehaus Capital Management and Ghost Tree Capital Group, LP, as well as additional U.S.... read more
First ever NHS ovarian cancer early detection service pilot announced.   UCLH Cancer Collaborative has today launched the first pilot project of an NHS ovarian cancer surveillance service for women who carry a faulty BRCA gene and have chosen not to have their ovaries and fallopian tubes removed.   The pilot, known as the ALDO project (Avoiding Late Diagnosis in Ovarian Cancer), aims to recruit 2,000 women aged over 35 from across England [1] and will use Abcodia’s ROCA© Test as part of an NHS service to detect ovarian cancer amongst BRCA-carriers before they have any symptoms. The ROCA Test... read more
London, August 30, 2018: Phrasee, the London-headquartered marketing technology company that uses artificial intelligence (AI) to generate optimised marketing copy, has closed a $4m Series A funding round. The investment will fuel Phrasee’s international growth plans, including scaling up its new US operation in San Francisco and the recently announced expansion of its UK team.   Albion Capital led the round, with follow-on funds from existing investors including global digital communications business Next Fifteen PLC (Next 15) and angel syndicate Galvanise Capital. Next 15 and Galvanise... read more
MeiraGTx
UCL Technology Fund investment MeiraGTx Holdings plc (‘MeiraGTx’), the clinical stage gene therapy company, has raised $75million at IPO, pricing five million shares at $15.00 per share on the Nasdaq Global Select Market on June 12 2018. The UCL Technology Fund (UCLTF) is managed by Albion Capital in collaboration with UCL Business (UCLB), UCL’s commercialisation company, and is dedicated to bringing UCL’s world-class research in life and physical sciences to commercial reality. MeiraGTx is its first investment to IPO. MeiraGTx has strong roots in UCL; its rare eye diseases business was borne... read more
uMotif
uMotif, the data capture company putting patients at the centre of clinical research, has raised £2.4 million in its latest funding round led by Albion Capital, the leading independent investment manager, along with several angel investors. uMotif’s software platform provides the patient-facing technology required to capture real-world data (eCOA, ePRo, eConsent) for the next generation of clinical research initiatives – from early phase to post-marketing trials. The technology is already in use by top pharma companies across Europe and North America, including AstraZeneca, Novartis and UCB... read more

Pages